Pathways for the processing and presentation of antigens to T cells
- PMID: 7722412
- DOI: 10.1002/jlb.57.4.543
Pathways for the processing and presentation of antigens to T cells
Abstract
Two pathways exist within vertebrate cells to generate peptides for recognition by T cells. The "endogenous" pathway provides peptides to MHC class I molecules for presentation to CD8+ T cells. These peptides are derived from proteins synthesized or residing in the cytoplasm or nucleus, and involves proteasomes and the ubiquitin pathway of protein degradation, as well as a specific peptide transporter (TAP) that allows these peptides access to the lumen of the endoplasmic reticulum. The exogenous pathway provides peptides to MHC class II molecules for presentation to CD4+ T cells. These peptides are derived from extracellular antigens taken up by endocytosis and degraded in the endosomal/lysosomal pathway. Peptide loading of MHC class II molecules requires the presence of a molecule (H-2M in mouse, HLA-DM in humans) that is structurally related to MHC class II molecules, but the mechanistic basis of this requirement is unknown. The class II region of the MHC contains a cluster of genes encoding proteins involved in antigen processing, including genes for two proteasome subunits (LMP2 and LMP7), the peptide transporter heterodimer (TAP1 and TAP2), and the H-2M/HLA-DM molecule (Ma and Mb, or DMA and DMB).
Similar articles
-
Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.Eur J Immunol. 1994 Aug;24(8):1863-8. doi: 10.1002/eji.1830240822. Eur J Immunol. 1994. PMID: 8056044
-
Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules.Nature. 1992 Nov 12;360(6400):171-4. doi: 10.1038/360171a0. Nature. 1992. PMID: 1436094
-
Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.J Immunol. 2005 Feb 15;174(4):1811-9. doi: 10.4049/jimmunol.174.4.1811. J Immunol. 2005. PMID: 15699107
-
Peptides bound to major histocompatibility complex molecules.Peptides. 1998;19(1):179-98. doi: 10.1016/s0196-9781(97)00277-5. Peptides. 1998. PMID: 9437752 Review.
-
Proteasome and class I antigen processing and presentation.Mol Biol Rep. 1995;21(1):53-6. doi: 10.1007/BF00990971. Mol Biol Rep. 1995. PMID: 7565665 Review.
Cited by
-
The genetic basis of graves' disease.Curr Genomics. 2011 Dec;12(8):542-63. doi: 10.2174/138920211798120772. Curr Genomics. 2011. PMID: 22654555 Free PMC article.
-
Association of LMP/TAP gene polymorphisms with tuberculosis susceptibility in Li population in China.PLoS One. 2012;7(3):e33051. doi: 10.1371/journal.pone.0033051. Epub 2012 Mar 12. PLoS One. 2012. PMID: 22427944 Free PMC article.
-
Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells.Cancer Immunol Immunother. 2012 Jun;61(6):881-92. doi: 10.1007/s00262-011-1157-5. Epub 2011 Nov 17. Cancer Immunol Immunother. 2012. PMID: 22089857 Free PMC article.
-
Us9, a stable lysine-less herpes simplex virus 1 protein, is ubiquitinated before packaging into virions and associates with proteasomes.Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13973-8. doi: 10.1073/pnas.94.25.13973. Proc Natl Acad Sci U S A. 1997. PMID: 9391137 Free PMC article.
-
Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.J Exp Med. 1997 Mar 3;185(5):909-20. doi: 10.1084/jem.185.5.909. J Exp Med. 1997. PMID: 9120397 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous